Drug resistance mechanisms of acute myeloid leukemia stem cells
J Niu, D Peng, L Liu - Frontiers in Oncology, 2022 - frontiersin.org
Acute myeloid leukemia (AML) is a polyclonal and heterogeneous hematological
malignancy. Relapse and refractory after induction chemotherapy are still challenges for …
malignancy. Relapse and refractory after induction chemotherapy are still challenges for …
Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: past discoveries and future directions
NJ Short, H Kantarjian - American journal of hematology, 2022 - Wiley Online Library
Azacitidine and decitabine are hypomethylating agents that have dose‐dependent
epigenetic and cytotoxic effects and are widely used in the treatment of myelodysplastic …
epigenetic and cytotoxic effects and are widely used in the treatment of myelodysplastic …
Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation
NJ Short, F Ong, F Ravandi… - Blood …, 2023 - ashpublications.org
Although venetoclax-based lower-intensity regimens have greatly improved outcomes for
older adults with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy …
older adults with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy …
Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia
NJ Short, H Kantarjian - The Lancet Haematology, 2022 - thelancet.com
The outcomes of older patients with acute myeloid leukaemia are inferior to their younger
counterparts, because, in part, of a more aggressive disease biology and poorer tolerance of …
counterparts, because, in part, of a more aggressive disease biology and poorer tolerance of …
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure
NJ Short, S Venugopal, W Qiao, TM Kadia… - Journal of hematology & …, 2022 - Springer
Background Treated secondary acute myeloid leukemia (ts-AML)—ie, AML arising from a
previously treated antecedent hematologic disorder—is associated with very poor outcomes …
previously treated antecedent hematologic disorder—is associated with very poor outcomes …
The evolution of research and therapy with hypomethylating agents in acute myeloid leukemia and myelodysplastic syndrome: New directions for old drugs
NJ Short, H Dombret, L Adès, H Kantarjian - The Cancer Journal, 2022 - journals.lww.com
Azacitidine and decitabine are cytosine analogs that function as DNA methyltransferase
inhibitors. These agents, commonly referred to as “hypomethylating agents,” are widely used …
inhibitors. These agents, commonly referred to as “hypomethylating agents,” are widely used …
Validation of ALFA 1200 score in patients with AML> 60 years treated with double nucleoside–based low-intensity therapy
S Venugopal, G Borthakur, N Daver… - Blood …, 2022 - ashpublications.org
COI notes: ND has received research funding from Daiichi-Sankyo, Bristol-Myers Squibb,
Pfizer, Gilead, Sevier, Genentech, Astellas, Daiichi-Sankyo, Abbvie, Hanmi, Trovagene …
Pfizer, Gilead, Sevier, Genentech, Astellas, Daiichi-Sankyo, Abbvie, Hanmi, Trovagene …
Is allogeneic transplantation the preferred therapy for older patients with acute myeloid leukemia?
A Ganser - Haematologica, 2022 - haematologica.org
The treatment of acute myeloid leukemia (AML) has seen tremendous developments over
the last few years, but treatment approaches and results are predominantly determined by …
the last few years, but treatment approaches and results are predominantly determined by …